Aisha I Abdullah PhD,  —

A four-year, $441,000 grant from the National Institutes of Health (NIH) will support research into the role of the gut microbiome — the population of microorganisms living in the intestines— in neuroinflammation and memory loss in people with Parkinson’s disease. The grant was given to scientists at California State University, San…

Fecal transplants — when patients receive a transplant of healthy gut microbiota into their intestines — were found to alleviate gastrointestinal problems, including constipation, and lessen both motor and non-motor symptoms in people with Parkinson’s disease, a small study showed. The results of…

Gain Therapeutics‘ investigational compounds were able to lessen motor symptoms in a rat model of GBA1-associated Parkinson’s disease and also decrease the levels of alpha-synuclein accumulation in nerve cells — two hallmarks of the neurodegenerative disease. The two candidates — GT-02287 and GT-02329 — are…

Treatment with investigational oral therapy BIIB122/DNL151 safely lowered the activity of disease biomarkers that reflect LRRK2 activity, a protein whose mutations are associated with Parkinson’s disease, according to results from two Phase 1 clinical studies. Plans are being put in place to advance the therapy into late-stage clinical testing…

PharmaTher is seeking regulatory approval to launch a clinical trial of the painkiller ketamine for levodopa-induced dyskinesia — the uncontrolled, involuntary movements that affect as many as 80% of Parkinson’s patients following treatment. The company, which focuses on the research and development of psychedelic pharmaceuticals, has submitted an…

Invitae has launched a new genetic testing program, at no charge to participants, to test adults suspected of having — or at risk of developing — neurodegenerative disorders, including Parkinson’s disease. The Adult Neurodegenerative Disorders sponsored testing…

Exercise can slow early cognitive decline in Parkinson’s disease patients who have a variant of the APOE gene, called APOE4, a recent study has found. “Additional research is needed to confirm our findings, but these results would support the use…

People with a sleep disorder marked by the physical “acting out” of vivid dreams — a condition considered an early form of  Parkinson’s disease — show changes in specific immune cells in the blood that directly relate to inflammation and damage to dopamine neurons in the brain, researchers…

People diagnosed with rheumatoid arthritis (RA) are at a significantly lower risk of developing Parkinson’s disease (PD) five or more years later, according to a large Swedish population study. This lesser risk — a drop of at least 35% —  is possibly due to the anti-inflammatory…

An investigative disease-modifying treatment by Yumanity Therapeutics, called YTX-7739, was found to improve motor skills and lessen toxic protein clumping in a mouse model of Parkinson’s disease (PD), the company reported in a press release. Data…